GILGAMESH PHARMA Trademark

Trademark Overview


On Thursday, July 9, 2026, a trademark application was filed for GILGAMESH PHARMA with the United States Patent and Trademark Office. The USPTO has given the GILGAMESH PHARMA trademark a serial number of 99932547. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, July 9, 2026. This trademark is owned by GILGAMESH PHARMACEUTICALS, INC.. The GILGAMESH PHARMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, pharmaceutical and drug preparations and substances for use in treating cancer and for use in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, schizophrenia, and longevity; Diagnostic biomarker reagents for pharmaceutical and medical purposes; predictive biomarker reagents for medical use, namely, for pharmaceuticals and drugs for use in treating cancer and in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, ...
gilgamesh pharma

General Information


Serial Number99932547
Word MarkGILGAMESH PHARMA
Filing DateThursday, July 9, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, July 9, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkGILGAMESH PHARMACEUTICAL
Goods and ServicesPharmaceuticals, namely, pharmaceutical and drug preparations and substances for use in treating cancer and for use in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, schizophrenia, and longevity; Diagnostic biomarker reagents for pharmaceutical and medical purposes; predictive biomarker reagents for medical use, namely, for pharmaceuticals and drugs for use in treating cancer and in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, schizophrenia, and longevity
NOT AVAILABLE"PHARMA"
Pseudo MarkGILGAMESH PHARMACEUTICALS

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 9, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGILGAMESH PHARMACEUTICALS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003
US

Trademark Events


Event DateEvent Description
Thursday, July 9, 2026NEW APPLICATION ENTERED
Thursday, July 9, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 9, 2026APPLICATION FILING RECEIPT MAILED